In April 2022, a phase 1 clinical trial (NCT05013216) based on a mutant KRAS-targeted long peptide vaccine combined with the adjuvant poly-ICLC was initiated at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins for patients at high risk of developing PDA and pancreatic cystic neoplasm. The gene discussed is KRAS; the disease is Patent ductus arteriosus.